In a pharmacy in Provo, Utah, USA, a pharmacist proudly displays boxes of Eli Lilly & Co.’s Mounjaro brand tirzepatide medication. This image captures the essence of success and growth for Eli Lilly, as the demand for weight loss and diabetes treatments continues to rise. Outgoing Chief Financial Officer Anat Ashkenazi shared with CNBC the company’s plans to build on this momentum.
Having played a crucial role in managing the surge in revenue and investor confidence stemming from Eli Lilly’s diabetes injection Mounjaro and the newly introduced obesity drug Zepbound, Ashkenazi is set to take on the role of CFO at Alphabet starting July 31. Her expertise and dedication have been evident since she assumed the CFO position at Eli Lilly in 2021, following a successful career spanning two decades with the pharmaceutical giant. Earlier this year, Ashkenazi was recognized on CNBC’s prestigious Changemakers list.
“To succeed in this industry, one must truly immerse themselves in the business, becoming a master of its intricacies and challenges,” she emphasized.
2024-06-17 08:00:01
Read more on www.cnbc.com